We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Santalis Pharmaceuticals, Inc. announced today the Notice of Allowance by the United States Patent Office of a patent containing nine claims covering the use of East Indian sandalwood...
Data supporting the use of East Indian sandalwood oil (EISO) for the treatment of psoriasis was presented by Dr. Manju Sharma, of the Vancouver Prostate Centre, at the recent 7th Euro-Global...
Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis Pharmaceuticals today announced it has obtained allowance from the...
Santalis Pharmaceuticals, Inc. announced today the issuance by the Japanese Patent Office of a patent that covers sandalwood oil-containing compositions that can be used to treat a variety...
Santalis Pharmaceuticals today announced it has enrolled its first patient into a single-center, placebo-controlled, double-blinded, safety, efficacy and tolerability study using a unique 5...
Santalis Pharmaceuticals today announced positive results from its single-center, open-label, efficacy and tolerability proof-of-concept study using a proprietary 10% East Indian Sandalwood...
Santalis Healthcare Corporation (formerly ViroXis Corporation), a wholly owned subsidiary of TFS Corporation, Ltd. (ASX:TFC), is pleased to announce that the first subject has been enrolled...
http://www.fool.com.au/2015/03/30/heres-why-today-is-a-good-day-to-buy-tfs-corporation-limited-shares/
Company: TIB Financial (TIBB) Participation: TIB received preliminary approval and expects the Treasury to invest $37 million in the company's senior preferred shares, receiving warrants to buy...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions